{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:39:00Z","timestamp":1795034340204,"version":"4.10.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA127003"],"award-info":[{"award-number":["P50 CA127003"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA224068"],"award-info":[{"award-number":["U54CA224068"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"EIF | Stand Up To Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-DT22-17"],"award-info":[{"award-number":["SU2C-AACR-DT22-17"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>While BRAF inhibitor combinations with EGFR and\/or MEK inhibitors have improved clinical efficacy in BRAF<jats:sup>V600E<\/jats:sup> colorectal cancer (CRC), response rates remain low and lack durability. Preclinical data suggest that BRAF\/MAPK pathway inhibition may augment the tumor immune response. We performed a proof-of-concept single-arm phase 2 clinical trial of combined PD-1, BRAF and MEK inhibition with sparatlizumab (PDR001), dabrafenib and trametinib in 37 patients with BRAF<jats:sup>V600E<\/jats:sup> CRC. The primary end point was overall response rate, and the secondary end points were progression-free survival, disease control rate, duration of response and overall survival. The study met its primary end point with a confirmed response rate (24.3% in all patients; 25% in microsatellite stable patients) and durability that were favorable relative to historical controls of BRAF-targeted combinations alone. Single-cell RNA sequencing of 23 paired pretreatment and day 15 on-treatment tumor biopsies revealed greater induction of tumor cell-intrinsic immune programs and more complete MAPK inhibition in patients with better clinical outcome. Immune program induction in matched patient-derived organoids correlated with the degree of MAPK inhibition. These data suggest a potential tumor cell-intrinsic mechanism of cooperativity between MAPK inhibition and immune response, warranting further clinical evaluation of optimized targeted and immune combinations in CRC. ClinicalTrials.gov registration: NCT03668431.<\/jats:p>","DOI":"10.1038\/s41591-022-02181-8","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T17:03:13Z","timestamp":1674752593000},"page":"458-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":202,"title":["Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial"],"prefix":"10.1038","volume":"29","author":[{"given":"Jun","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry X.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Pelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9012-6982","authenticated-orcid":false,"given":"Marios","family":"Giannakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1387-4009","authenticated-orcid":false,"given":"Julian","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2187-0147","authenticated-orcid":false,"given":"Kelly","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vjola","family":"Jorgji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princy","family":"Sindurakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Braverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnav","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7362-3207","authenticated-orcid":false,"given":"Tomonori","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Spurrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill N.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9524-3600","authenticated-orcid":false,"given":"Jeffrey W.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea C.","family":"Enzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Enzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4062-0808","authenticated-orcid":false,"given":"Samuel J.","family":"Klempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-8301","authenticated-orcid":false,"given":"Nadine J.","family":"McCleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Meyerhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6184-9273","authenticated-orcid":false,"given":"Matthew B.","family":"Yurgelun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5778-9984","authenticated-orcid":false,"given":"Katie","family":"Kanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily E.","family":"Van Seventer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam","family":"Baiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Jarnagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4752-2677","authenticated-orcid":false,"given":"William B.","family":"Bradford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6037-7377","authenticated-orcid":false,"given":"Edmond","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa G.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6021-2713","authenticated-orcid":false,"given":"Isobel J.","family":"Fetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Siravegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo J.","family":"Gemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9736-2109","authenticated-orcid":false,"given":"Arlene","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7913-2641","authenticated-orcid":false,"given":"Shadmehr","family":"Demehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3863-9841","authenticated-orcid":false,"given":"Catarina D.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad A.","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5245-7841","authenticated-orcid":false,"given":"Aparna R.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2349-2656","authenticated-orcid":false,"given":"Nir","family":"Hacohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8173-5778","authenticated-orcid":false,"given":"Ryan B.","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"2181_CR1","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949\u2013954 (2002).","journal-title":"Nature"},{"key":"2181_CR2","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1200\/JCO.2009.22.4295","volume":"27","author":"SD Richman","year":"2009","unstructured":"Richman, S. D. et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J. Clin. Oncol. 27, 5931\u20135937 (2009).","journal-title":"J. Clin. Oncol."},{"key":"2181_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809\u2013819 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2181_CR4","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","volume":"379","author":"GS Falchook","year":"2012","unstructured":"Falchook, G. S. et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893\u20131901 (2012).","journal-title":"Lancet"},{"key":"2181_CR5","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","volume":"33","author":"S Kopetz","year":"2015","unstructured":"Kopetz, S. et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J. Clin. Oncol. 33, 4032\u20134038 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2181_CR6","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373, 726\u2013736 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2181_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","volume":"2","author":"RB Corcoran","year":"2012","unstructured":"Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227\u2013235 (2012).","journal-title":"Cancer Discov."},{"key":"2181_CR8","doi-asserted-by":"publisher","first-page":"ra84","DOI":"10.1126\/scisignal.2001148","volume":"3","author":"RB Corcoran","year":"2010","unstructured":"Corcoran, R. B. et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 3, ra84 (2010).","journal-title":"Sci. Signal."},{"key":"2181_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1158\/2159-8290.CD-14-1518","volume":"5","author":"LG Ahronian","year":"2015","unstructured":"Ahronian, L. G. et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 5, 358\u2013367 (2015).","journal-title":"Cancer Discov."},{"key":"2181_CR10","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N. Engl. J. Med. 381, 1632\u20131643 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2181_CR11","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1200\/JCO.2015.63.2471","volume":"33","author":"RB Corcoran","year":"2015","unstructured":"Corcoran, R. B. et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J. Clin. Oncol. 33, 4023\u20134031 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2181_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran, R. B. et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov. 8, 428\u2013443 (2018).","journal-title":"Cancer Discov."},{"key":"2181_CR13","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas, A. et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315, 1600\u20131609 (2016).","journal-title":"JAMA"},{"key":"2181_CR14","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803\u20131813 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2181_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413 (2017).","journal-title":"Science"},{"key":"2181_CR16","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJMc1510353","volume":"373","author":"Y Asaoka","year":"2015","unstructured":"Asaoka, Y., Ijichi, H. & Koike, K. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 373, 1979 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2181_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330\u2013337 (2012).","journal-title":"Nature"},{"key":"2181_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","volume":"44","author":"PJR Ebert","year":"2016","unstructured":"Ebert, P. J. R. et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44, 609\u2013621 (2016).","journal-title":"Immunity"},{"key":"2181_CR19","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","volume":"21","author":"L Liu","year":"2015","unstructured":"Liu, L. et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin. Cancer Res. 21, 1639\u20131651 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2181_CR20","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1158\/2159-8290.CD-20-0873","volume":"11","author":"A Hong","year":"2021","unstructured":"Hong, A. et al. Durable suppression of acquired MEK inhibitor resistance in cancer by sequestering MEK from ERK and promoting antitumor T-cell immunity. Cancer Discov. 11, 714\u2013735 (2021).","journal-title":"Cancer Discov."},{"key":"2181_CR21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","volume":"25","author":"PA Ascierto","year":"2019","unstructured":"Ascierto, P. A. et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat. Med. 25, 941\u2013946 (2019).","journal-title":"Nat. Med."},{"key":"2181_CR22","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","volume":"25","author":"A Ribas","year":"2019","unstructured":"Ribas, A. et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat. Med. 25, 936\u2013940 (2019).","journal-title":"Nat. Med."},{"key":"2181_CR23","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41591-019-0474-7","volume":"25","author":"RJ Sullivan","year":"2019","unstructured":"Sullivan, R. J. et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat. Med. 25, 929\u2013935 (2019).","journal-title":"Nat. Med."},{"key":"2181_CR24","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-020-1082-2","volume":"26","author":"R Dummer","year":"2020","unstructured":"Dummer, R. et al. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat. Med. 26, 1557\u20131563 (2020).","journal-title":"Nat. Med."},{"key":"2181_CR25","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1158\/1078-0432.CCR-19-3579","volume":"26","author":"G Middleton","year":"2020","unstructured":"Middleton, G. et al. BRAF-mutant transcriptional subtypes predict outcome of combined BRAF, MEK, and EGFR blockade with dabrafenib, trametinib, and panitumumab in patients with colorectal cancer. Clin. Cancer Res. 26, 2466\u20132476 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2181_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/1078-0432.CCR-16-0140","volume":"23","author":"D Barras","year":"2017","unstructured":"Barras, D. et al. BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin. Cancer Res. 23, 104\u2013115 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2181_CR27","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350\u20131356 (2015).","journal-title":"Nat. Med."},{"key":"2181_CR28","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","volume":"184","author":"K Pelka","year":"2021","unstructured":"Pelka, K. et al. Spatially organized multicellular immune hubs in human colorectal cancer. Cell 184, 4734\u20134752 (2021).","journal-title":"Cell"},{"key":"2181_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2159-8290.CD-17-1227","volume":"8","author":"M Hazar-Rethinam","year":"2018","unstructured":"Hazar-Rethinam, M. et al. Convergent therapeutic strategies to overcome the heterogeneity of acquired resistance in BRAF(V600E) colorectal cancer. Cancer Discov. 8, 417\u2013427 (2018).","journal-title":"Cancer Discov."},{"key":"2181_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217\u2013223 (2019).","journal-title":"Nature"},{"key":"2181_CR31","doi-asserted-by":"publisher","first-page":"12-12","DOI":"10.1200\/JCO.2022.40.16_suppl.3598","volume":"40","author":"VK Morris","year":"2022","unstructured":"Morris, V. K. et al. Phase I\/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. J. Clin. Oncol. 40, 12-12 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2181_CR32","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","volume":"20","author":"C Eng","year":"2019","unstructured":"Eng, C. et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 20, 849\u2013861 (2019).","journal-title":"Lancet Oncol."},{"key":"2181_CR33","doi-asserted-by":"publisher","first-page":"e20201414","DOI":"10.1084\/jem.20201414","volume":"218","author":"C Fedele","year":"2021","unstructured":"Fedele, C. et al. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. J. Exp. Med. 218, e20201414 (2021).","journal-title":"J. Exp. Med."},{"key":"2181_CR34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"2181_CR35","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"2181_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"2181_CR37","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).","journal-title":"BMC Bioinformatics"},{"key":"2181_CR38","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1109\/TPAMI.2012.240","volume":"35","author":"VY Tan","year":"2013","unstructured":"Tan, V. Y. & Fevotte, C. Automatic relevance determination in nonnegative matrix factorization with the beta-divergence. IEEE Trans. Pattern Anal. Mach. Intell. 35, 1592\u20131605 (2013).","journal-title":"IEEE Trans. Pattern Anal. Mach. Intell."},{"key":"2181_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25\u201329 (2000).","journal-title":"Nat. Genet."},{"key":"2181_CR40","doi-asserted-by":"publisher","first-page":"D325","DOI":"10.1093\/nar\/gkaa1113","volume":"49","author":"Gene Ontology Consortium","year":"2021","unstructured":"Gene Ontology Consortium The Gene Ontology resource: enriching a GOld mine. Nucleic Acids Res. 49, D325\u2013D334 (2021).","journal-title":"Nucleic Acids Res."},{"key":"2181_CR41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"2181_CR42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"2181_CR43","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902 (2019).","journal-title":"Cell"},{"key":"2181_CR44","doi-asserted-by":"publisher","first-page":"W191","DOI":"10.1093\/nar\/gkz369","volume":"47","author":"U Raudvere","year":"2019","unstructured":"Raudvere, U. et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 47, W191\u2013W198 (2019).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02181-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02181-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02181-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T10:15:19Z","timestamp":1676888119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02181-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["2181"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-02181-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]},"assertion":[{"value":"12 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.X.C. is an employee of Google Ventures. M.G. receives research funding from Servier and Janssen. A.M. has served a consultant\/advisory role for Third Rock Ventures, Asher Biotherapeutics, Abata Therapeutics, Flare Therapeutics, venBio Partners, BioNTech, Rheos Medicines and Checkmate Pharmaceuticals; is an equity holder in Asher Biotherapeutics and Abata ThPerapeutics; and has a sponsored research agreement with Bristol Myers Squibb and Olink Proteomics. P.C.E. is\/has been a consultant and has received honoraria from ALX Oncology, Arcus Bioscience, Astellas, AstraZeneca, Blueprint Medicines, Chimeric Therapeutics, Celgene, Coherus, Daiichi-Sankyo, Five Prime, Ideaya, Istari, Legend, Lilly, Loxo, Merck, Novartis, Ono, Servier, Taiho, Takeda, Turning Point Therapeutics, Xencor and Zymeworks. S.J.K. has served a consultant\/advisory role for Astellas, Merck, Bristol Myers Squibb, Daiichi-Sankyo, Pieris, AstraZeneca, Natera, Eli Lilly, Mersana and Sanofi-Aventis. S.J.K. owns stock in Turning Point Therapeutics. J.A.M. has served as an advisor\/consultant to Merck Pharmaceutical and COTA Healthcare. M.B.Y. receives research funding from Janssen Pharmaceuticals. C.D.C. is an employee and shareholder of Novartis. N.H. receives research funding from Bristol Myers Squibb, has equity in BioNTech and advises and has equity in Related Sciences\/Danger Bio. R.B.C. has received consulting or speaking fees from Abbvie, Amgen, Array Biopharma\/Pfizer, Asana Biosciences, Astex Pharmaceuticals, AstraZeneca, Avidity Biosciences, BMS, C4 Therapeutics, Chugai, Cogent Biosciences, Elicio, Erasca, Fog Pharma, Genentech, Guardant Health, Ipsen, Kinnate Biopharma, LOXO, Merrimack, Mirati Therapeutics, Natera, Navire, Nested Therapeutics, N-of-one\/Qiagen, Novartis, nRichDx, Remix Therapeutics, Revolution Medicines, Roche, Roivant, Shionogi, Shire, Spectrum Pharmaceuticals, Symphogen, Syndax, Tango Therapeutics, Taiho, Theonys, Warp Drive Bio and Zikani Therapeutics; holds equity in Avidity Biosciences, C4 Therapeutics, Cogent Biosciences, Erasca, Kinnate Biopharma, Interline Therapeutics, Nested Therapeutics, nRichDx, Remix Therapeutics, Revolution Medicines and Theonys; is a cofounder, equity holder and board member of Alterome Therapeutics; and has received research funding from Asana, AstraZeneca, Lilly, Novartis and Pfizer. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}